Eltrombopag is prescribed for:
- Chronic immune thrombocytopenia (ITP)
- Thrombocytopenia in chronic hepatitis C
- Severe aplastic anemia
- Hematology platelet disorders
Stimulates bone marrow to produce more platelets.
Generic Name: Eltrombopag
Brand Names: Promacta
Eltrombopag is an oral thrombopoietin receptor agonist that stimulates platelet production.
Eltrombopag is prescribed for:
Stimulates bone marrow to produce more platelets.
Common side effects:
Serious side effects:
Eltrombopag is an oral thrombopoietin receptor agonist that increases platelet production.
Must be taken on empty stomach - avoid dairy, antacids, and mineral supplements within 4 hours.
Requires liver function monitoring due to hepatotoxicity risk.
For more information, see MedlinePlus.
This medication is commonly used to treat or manage the following conditions:
Thrombocytopenia, a condition of low platelet count (below 150,000/microliter), can cause easy bruising and bleeding due to impaired clotting from decreased production, increased destruction, or splenic sequestration.
Anemia, characterized by a low red blood cell count, leads to fatigue and weakness due to reduced oxygen delivery; causes include blood loss, decreased production, and chronic diseases.
Chronic hepatitis, a long-term liver inflammation often caused by viral infections, autoimmune disorders, or metabolic issues, can lead to serious complications if undiagnosed.
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Loading questions...
Have questions about Eltrombopag? Get expert answers from Dr. Zimmer.
Privacy: Your questions are posted anonymously for your health privacy. Your name and email are only used for admin purposes.
Questions are reviewed before posting. You'll see your question and Dr. Zimmer's answer below once approved.